Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    Cancer MESHD Patient Management Strategy in a Cancer Center of Zhejiang, China During the COVID-19 Pandemic 

    Authors: Song-xiao Xu; Xiang-dong Cheng; Zhi-wen Pan; Qian Song; Yi-hong Wang; Juan Xiong; Yong-yi Chen; Fan Fan; Jing Zhu; Wan-ying Wu; Xue-ying Deng; Yan-pin Yu; Xiao-hong Xu; Wen-hu Chen; Tao Zhu; Yang Yu; Kai-zhong Liu; Guo-liang Shao; Ming Chen; En-yan Yu

    doi:10.21203/rs.3.rs-30259/v2 Date: 2020-05-19 Source: ResearchSquare

    Background: Due to the increased risk of viral infection and the severe HP iral infection MESHDand the severe shortage of medical resources during the pandemic of COVID-19, most hospitals in the epidemic areas significantly reduced non-emergency admissions and services, if not closed. As a result, it has been difficult to treat c ancer MESHDpatients on time, which adversely affects their prognosis. To address this problem, c ancer MESHDcenters must develop a strategic plan to manage both inpatients and outpatients during the pandemic, provide them with the necessary treatment, and at the same time prevent the spread of the virus among patients, visitors and medical staff. Methods: Based upon the epidemic situation in Zhejiang Province, China, the number of running non-emergency medical wards in the Zhejiang Cancer Hospital was gradually increased in a controlled manner. All staff of the hospital received COVID-19 preventive training and was provided with three different levels of protection according to the risks of their services. Only patients without a known history of SARS-CoV-2 contact were eligible to schedule an appointment. Body temperature was measured on all patients upon their arrival at the hospital. Chest CT image, blood SERO cell counting and travel TRANS/contact history were investigated in patients with fever HP ever. MESHD Respiratory tract samples, such as sputum and throat swabs, from all patients, including those clinically suspected of S ARS-CoV-2 infection, MESHD were collected for nucleic acid detection of SARS-CoV-2 before treatment.Results: A total of 3697 inpatients and 416 outpatients seeking c ancer MESHDtreatment were enrolled from February 1 to April 3, 2020, in compliance with the hospital’s infection-control interventions. The clinicopathological parameters of the patients were summarized herein. 4237 samples from 4101 patients produced negative RNA testing results. Four clinically suspected patients all presented negative RNA test results and were excluded from the S ARS-CoV-2 infection MESHDthrough follow-up retesting and monitoring. Seven patients with only N-gene positive results were retested, followed by CT scan and SARS-CoV-2 contact history investigation. All of them were finally diagnosed as non-infected patients. There was one outpatient who was confirmed positive by virus RNA test and then followed up. She might be an asymptomatic laboratory- confirmed case TRANS. During the study period, there was no S ARS-CoV-2 infection MESHDamong staff, patients and escorts of patients in the Zhejiang Cancer Hospital.Conclusion: This study suggested our infection-control interventions, including viral nucleic acid test, could be used as a reliable method to screen c ancer MESHDpatients in the area with moderate COVID-19 prevalence SERO. C ancer MESHDmay not be a high-risk factor of S ARS-CoV-2 infection. MESHD 

    Cancer MESHD Patient Management Strategy in a Cancer Center of Zhejiang, China During the COVID-19 Pandemic

    Authors: Song-xiao Xu; Xiang-dong Cheng; Zhi-wen Pan; Qian Song; Yi-hong Wang; Juan Xiong; Yong-yi Chen; Fan Fan; Jing Zhu; Wan-ying Wu; Xue-ying Deng; Yan-pin Yu; Xiao-hong Xu; Wen-hu Chen; Tao Zhu; Yang Yu; Kai-zhong Liu; Guo-liang Shao; Ming Chen; En-yan Yu

    doi:10.21203/rs.3.rs-30259/v3 Date: 2020-05-19 Source: ResearchSquare

    Background: Due to the increased risk of viral infection and the severe HP viral infection and the severe MESHD shortage of medical resources during the pandemic of COVID-19, most hospitals in the epidemic areas significantly reduced non-emergency admissions and services, if not closed. As a result, it has been difficult to treat cancer MESHD patients on time, which adversely affects their prognosis. To address this problem, cancer MESHD centers must develop a strategic plan to manage both inpatients and outpatients during the pandemic, provide them with the necessary treatment, and at the same time prevent the spread of the virus among patients, visitors and medical staff. Methods: Based upon the epidemic situation in Zhejiang Province, China, the number of running non-emergency medical wards in the Zhejiang Cancer Hospital was gradually increased in a controlled manner. All staff of the hospital received COVID-19 preventive training and was provided with three different levels of protection according to the risks of their services. Only patients without a known history of SARS-CoV-2 contact were eligible to schedule an appointment. Body temperature was measured on all patients upon their arrival at the hospital. Chest CT image, blood SERO cell counting and travel TRANS/contact history were investigated in patients with fever HP fever MESHD. Respiratory tract samples, such as sputum and throat swabs, from all patients, including those clinically suspected of SARS-CoV-2 infection MESHD, were collected for nucleic acid detection of SARS-CoV-2 before treatment.Results: A total of 3697 inpatients and 416 outpatients seeking cancer MESHD treatment were enrolled from February 1 to April 3, 2020, in compliance with the hospital’s infection-control interventions. The clinicopathological parameters of the patients were summarized herein. 4237 samples from 4101 patients produced negative RNA testing results. Four clinically suspected patients all presented negative RNA test results and were excluded from the SARS-CoV-2 infection MESHD through follow-up retesting and monitoring. Seven patients with only N-gene positive results were retested, followed by CT scan and SARS-CoV-2 contact history investigation. All of them were finally diagnosed as non-infected patients. There was one outpatient who was confirmed positive by virus RNA test and then followed up. She might be an asymptomatic laboratory- confirmed case TRANS. During the study period, there was no SARS-CoV-2 infection MESHD among staff, patients and escorts of patients in the Zhejiang Cancer Hospital.Conclusion: This study suggested our infection-control interventions, including viral nucleic acid test, could be used as a reliable method to screen cancer MESHD patients in the area with moderate COVID-19 prevalence SERO. Cancer MESHD may not be a high-risk factor of SARS-CoV-2 infection MESHD

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.